Want to see PTGX full AI Analyst Report?
PTGX Stock Chart & Stats
$105.98
-$0.87(-2.26%)
At close: 4:00 PM EST
$105.98
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$50.49 - $143.29
Previous CloseN/A
Volume120.35K
Average Volume (3M)824.54K
Market Cap
$8.71B
Enterprise Value$6.89K
Total Cash (Recent Filing)$547.79M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Jul 30, 2026EPS Estimate
2.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding64,311,370
10 Day Avg. Volume768,486
30 Day Avg. Volume824,542
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$131.11Price Target Upside23.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.23
Revenue Forecast (FY)$524.67M
Bulls Say, Bears Say
Bulls Say
Low Leverage, Strong Equity BaseA conservative capital structure with very low debt and substantial equity provides durable funding flexibility for clinical R&D, lowers refinancing risk, and lets management absorb operating swings without immediate external financing, supporting long-term pipeline development.
Revenue Acceleration And High Gross MarginsSustained revenue acceleration plus near-100% gross margins are structural positives for a biotech model: once programs advance, incremental revenues can flow largely to the bottom line, providing high operating leverage if R&D and SG&A are managed while commercialization or partner payments scale.
Governance Continuity And Incentive AlignmentRe-election of directors, auditor ratification, and adoption of a new equity incentive plan signal governance stability and long-term employee/management alignment. Stable board oversight and aligned incentives support consistent strategic execution across clinical milestones.
Bears Say
Renewed Cash BurnMaterial negative operating and free cash flow over the TTM increases reliance on the balance sheet or fresh financing. Persisting burn pressures capital allocation, risks future dilution, and can constrain program funding or strategic optionality absent recurring commercial revenues.
Profitability Volatility And Deep LossesSharp swings from prior profitability to heavy current losses indicate low earnings quality and execution or timing risk. Such volatility weakens predictability of future cash flows, complicates partner negotiations and planning, and elevates the probability of future financing needs.
No Commercial Products; Revenue LumpyDependence on collaboration payments, upfronts and milestones yields lumpy, milestone-driven revenue rather than recurring sales. Without approved products, long-term sustainability hinges on successful partnerships or approvals, increasing execution and revenue timing risk.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics Inc’s price range in the past 12 months?
Protagonist Therapeutics Inc lowest stock price was $50.48 and its highest was $143.29 in the past 12 months.
What is Protagonist Therapeutics Inc’s market cap?
Protagonist Therapeutics Inc’s market cap is $8.71B.
When is Protagonist Therapeutics Inc’s upcoming earnings report date?
Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 5 days.
How were Protagonist Therapeutics Inc’s earnings last quarter?
Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.55.
Is Protagonist Therapeutics Inc overvalued?
According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued.
Does Protagonist Therapeutics Inc pay dividends?
Protagonist Therapeutics Inc does not currently pay dividends.
What is Protagonist Therapeutics Inc’s EPS estimate?
Protagonist Therapeutics Inc’s EPS estimate is 2.23.
How many shares outstanding does Protagonist Therapeutics Inc have?
Protagonist Therapeutics Inc has 64,311,370 shares outstanding.
What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?
Protagonist Therapeutics Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went up 4.798%.
Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.11 (23.71% Upside)
$131.11 (23.71% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 278.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$131.11
▲(23.71% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.19% Insiders
26.61% Mutual Funds
0.41% Other Institutional Investors
44.82% Public Companies and
Individual Investors